Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph P Insinga

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Lower Genital Tract Disease|December 31, 2009
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured populationHenry J Henk, Ralph P Insinga, Puneet K Singhal, et al.
Gynecologic Oncology|September 2, 2008
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health planRalph P Insinga, Xin Ye, Puneet K Singhal, et al.
Journal of Medical Economics|June 8, 2021
Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-upRalph P Insinga, Josephine L Feliciano, Nan Qiao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 17, 2008
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United StatesRalph P Insinga, Kai-Li Liaw, Lisa G Johnson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 23, 2007
Abnormal outcomes following cervical cancer screening: event duration and health utility lossRalph P Insinga, Andrew G Glass, Evan R Myers, et al.
Rheumatology and Therapy|April 11, 2018
Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in ScotlandRebekah H Borse, Sumesh Kachroo, Chloe Brown, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
Current Medical Research and Opinion|July 30, 2008
Five-year routine cervical cancer screening rates and intervals in a US health planVernon F Schabert, Xin Ye, Ralph P Insinga, et al.
Infectious Agents and Cancer|July 14, 2007
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectivesRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Lower Genital Tract Disease|December 31, 2009
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured populationHenry J Henk, Ralph P Insinga, Puneet K Singhal, et al.
Gynecologic Oncology|September 2, 2008
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health planRalph P Insinga, Xin Ye, Puneet K Singhal, et al.
Journal of Medical Economics|June 8, 2021
Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-upRalph P Insinga, Josephine L Feliciano, Nan Qiao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 17, 2008
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United StatesRalph P Insinga, Kai-Li Liaw, Lisa G Johnson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 23, 2007
Abnormal outcomes following cervical cancer screening: event duration and health utility lossRalph P Insinga, Andrew G Glass, Evan R Myers, et al.
Rheumatology and Therapy|April 11, 2018
Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in ScotlandRebekah H Borse, Sumesh Kachroo, Chloe Brown, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
Current Medical Research and Opinion|July 30, 2008
Five-year routine cervical cancer screening rates and intervals in a US health planVernon F Schabert, Xin Ye, Ralph P Insinga, et al.
Infectious Agents and Cancer|July 14, 2007
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectivesRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Pageof 5